CRLX101 is an investigational drug.
There have been 12 clinical trials for CRLX101.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Cerulean Pharma Inc., NewLink Genetics Corporation, and National Cancer Institute (NCI).